Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Professor Nicholas Paton

Professor of Infectious Diseases

United Kingdom

Jump to: Affiliations Publications

Affiliations
Department of Clinical Research
Faculty of Infectious and Tropical Diseases

Selected Publications
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
Rowland, T; FitzGerald, R; Challenger, E; Dickinson, L; Else, LJ; Walker, L; Hale, C; Shaw, V; Kelly, C; Lyon, R; Gibney, J; Dhamani, K; Irwin, M; Enever, Y; Tetlow, M; Wood, W; Reynolds, H; Chiong, J; Osanlou, O; Pertinez, H; Bullock, K; Greenhalf, W; Owen, A; Lalloo, DG; Jacobs, M; ... AGILE CST‐6 Study Group,
2026
Clinical pharmacology and therapeutics
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Kityo, C; Mambule, IK; Musaazi, J; Sokhela, S; Mugerwa, H; Yawe, I; CRESSWELL, F; Siika, A; Kosgei, J; Shah, R; Naidoo, L; Opiyo, K; Otike, C; Möller, K; Okwero, M; Wambui, C; Van Eygen, V; Mohammed, P; Addo Boateng, F; PATON, NI; CARES trial team,;
2025
Nature medicine
Optimised second-line regimens in the public health approach.
PATON, NI;
2025
The lancet. HIV
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.
Orkin, C; Paterson, A; Elias, A; Smuk, M; Ring, K; Volny-Anne, A; Calmy, A; Hazra, A; Geretti, AM; Radix, A; Titanji, BK; Spire, B; Del Rio, C; Foster, C; Moore, CB; Cortes, CP; Mussini, C; Kuritzkes, DR; Tan, DH S; Martinez, E; Wit, FW N M; CRESSWELL, F; Venter, WD F; Levy, I; Zucker, J; ... Paparini, S.
2025
The lancet. HIV
Evaluation for fungal pulmonary infections is essential in suspected tuberculosis relapse - Authors' reply.
PATON, NI; Cousins, C; Chew, KL;
2025
The Lancet. Infectious diseases
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.
PATON, NI; Cousins, C; Sari, IP; Burhan, E; Ng, N-K; Dalay, VB; Suresh, C; Kusmiati, T; Chew, KL; Balanag, VM; Lu, Q; Ruslami, R; Djaharuddin, I; Sugiri, JJ R; Veto, RS; Sekaggya-Wiltshire, C; Avihingsanon, A; Saini, JK; Papineni, P; Nunn, AJ; Crook, AM; TRUNCATE-TB Trial Team,;
2025
The Lancet. Infectious diseases
PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment.
Cross, GB; Sari, IP; Burkill, SM; Yap, CW; Nguyen, H; Quyet, D; Dalay, VB; Gutierrez, E; Balanag, VM; Castillo, RJ; Chang, CC; Kelleher, AD; O'Doherty, J; PATON, NI;
2024
Nature communications
Quantitative drug susceptibility testing for Mycobacterium tuberculosis using unassembled sequencing data and machine learning.
CRyPTIC consortium,;
2024
PLoS computational biology
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo, C; Mambule, IK; Musaazi, J; Sokhela, S; Mugerwa, H; Ategeka, G; Cresswell, F; Siika, A; Kosgei, J; Shah, R; Naidoo, L; Opiyo, K; Otike, C; Möller, K; Kaimal, A; Wambui, C; Van Eygen, V; Mohammed, P; Addo Boateng, F; PATON, NI; CARES trial team,;
2024
The Lancet. Infectious diseases
Target regimen profiles for tuberculosis treatment.
Lienhardt, C; Dooley, KE; Nahid, P; Wells, C; Ryckman, TS; Kendall, EA; Davies, G; Brigden, G; Churchyard, G; Cirillo, DM; Di Meco, E; Gopinath, R; Mitnick, C; Scott, C; Amanullah, F; Bansbach, C; Boeree, M; Campbell, M; Conradie, F; Crook, A; Daley, CL; DHEDA, K; Diacon, A; Gebhard, A; Hanna, D; ... Schumacher, SG.
2024
Bulletin of the World Health Organization
See more information

Contact

United Kingdom